Court Blocks DOJ Subpoena Targeting Trans Youth Healthcare

Judge stops DOJ subpoena: a win in safeguarding transgender healthcare privacy

In a groundbreaking decision, a federal judge threw out a Department Department Justice (DOJ) subpoena that was trying force Children's National Hospital in Washington, D.C., hand over private details about young patients receiving gender-affirming care. This ruling marks a major setback DOJ's push limit access gender-affirming care transgender youth. Interestingly, hospital had already stopped offering such care last July after current presidential administration threatened cut funding from institutions providing it.

The fight over privacy and rights

The legal drama revolved around eight families whose children received transition-related healthcare through hospital's Gender Development Program between 2020 and 2025. These families argued that DOJ's subpoena, which sought sensitive info like addresses, social security numbers, medical diagnoses, prescriptions, and parental consent papers, violated their Fourth Amendment rights against unreasonable searches and seizures, as well as their Fifth Amendment rights medical privacy. The DOJ claimed families couldn't legally challenge subpoena since it wasn't served directly them but hospital staff. Plus, said families were challenging it after compliance deadline had passed. However, U.S. District Judge Julie Rubin saw things differently. She decided families did have legal standing, pointing out undue burden placed on them and noting children's reliance on their parents protect interests.

Protecting legal standing and medical privacy

Judge Rubin ruled that DOJ's subpoena lacked a valid investigatory purpose and seemed driven more by Executive's goal end access gender-affirming healthcare teens. Judge found no logical link between subpoena's demands and its supposed goals. Last year, DOJ had sent subpoenas 20 medical providers offering gender-affirming care transgender youth, claiming purpose was prevent healthcare fraud and unauthorized use puberty blockers and hormones. Yet, these medications have been safely used decades other conditions and transgender care without additional federal oversight. Judge Rubin pointed out that DOJ didn't offer solid proof, like affidavits or whistleblower reports, justify investigation hospital any healthcare wrongdoing. She stressed that Federal Food, Drug, Cosmetic Act regulates commerce, not patient care, and DOJ shouldn't need such sensitive info investigate possible healthcare fraud.

A key victory medical privacy

Judge concluded subpoena wasn't motivated by legitimate government purpose and was overly broad. She called it oppressive attempt intimidate and harass both hospital and families involved. While ruling specifically affects eight families who filed lawsuit, echoes similar decisions handed down federal judges recent months. Donovan Bendana, lawyer families and Liman Law Fellow GLBTQ Legal Advocates & Defenders (GLAD Law), hailed ruling as important win families and medical privacy, slamming government's misuse investigative power. Jennifer Levi, Senior Director Transgender Queer Rights GLAD Law, warned fear exposure private health info could keep families from getting essential medical care, risking their children's health. She stated court's decision safeguards involved families and reinforces key principles medical privacy all Americans. Eves Hill, partner Brown, Goldstein & Levy, highlighted that ruling confirms government can't interfere medical exam rooms or undermine healthcare choices families and their doctors make.

Impact government policy and resistance

Despite absence federal laws banning gender-affirming care, current administration has been trying cut it through executive orders. A blocked order from January aimed extend statute limitations lawsuits against gender-affirming doctors and crack down misleading claims about long-term impacts such care. Furthermore, a memo directed DOJ staff equate gender-affirming care minors with female genital mutilation, despite medical evidence otherwise, threatening severe punishments healthcare providers. According 2025 JAMA study, fewer than 3,000 teens receive puberty blockers or hormone therapy, yet these practices are supported by major U.S. medical groups as vital and life-saving young people with gender dysphoria. Critics have called federal government's strategy a "toxic plan," warning it endangers patients by potentially causing harmful psychological and physical setbacks. Judge's decision stands strong defense privacy and medical freedom against government overreach, protecting vulnerable families and highlighting ongoing resistance efforts undermine transgender healthcare rights.